超越ADCs:利用双特异性抗体直接诱导亡以进行向瘤根除
Victor S Goldmacher1, Iosif M Gershteyn1, Yelena Kovtun1
1Research and Development Department, ImmuVia, Inc., Cambridge, MA 02142, United States.
Antibody therapeutics
|March 10, 2025
概括
双特异性亡触发剂 (BAT) 通过激活亡,直接杀死癌细胞,比ADC和BiTE具有潜在的优势. 强大的临床前模型预测了这些新型癌症疗法的临床结果.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 双特异性亡触发剂 (BAT) 是一种新型双特异性抗体,旨在诱导癌细胞死亡.
- 最佳技术向瘤抗原和死亡受体,直接激活外部亡途径.
- 这种机制使BAT与抗体-药物合物 (ADC) 和免疫细胞参与剂 (BiTEs,NKCE) 有区别.
研究的目的:
- 评估BAT的潜在临床疗效和安全性.
- 分析临床前数据对DR5向抗体临床结果的预测价值.
- 突出在开发安全有效的抗癌疗法方面的进展.
主要方法:
- 对DR5向抗体的临床前和临床数据的分析.
- 比较BAT与现有的癌症疗法,如ADC和BTE.
- 在异种移植癌症模型和非人类灵长类动物中评估CancerlysinTM IMV-M.
主要成果:
- 针对DR5的抗体的临床前疗效与临床活性相关.
- 临床DR5向抗体通常耐受良好,表明安全性.
- 癌素TM IMV-M 在临床前模型中显示出强烈的疗效,并在灵长类动物中显示出安全性.
结论:
- 最佳技术 (BAT) 代表了一种有前途的新型抗癌药物类别,其有效性和安全性有可能得到提高.
- 临床前模型对于预测DR5向抗体的临床成功非常有价值.
- 癌症lysinTM IMV-M标志着在开发新型癌症治疗中迈出了重要的一步.
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Tumor Immunotherapy
457
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
457
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Cytotoxic T Cells-mediated Immune Response
825
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
825
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
107
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
107
The Intrinsic Apoptotic Pathway
5.9K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
5.9K


